NGNE (Neurogene) Retained Earnings: $-383.58 Mil (As of Mar. 2026)


NGNE Neurogene Inc NGNE
12 GF Score
Price $39.54
! 4 Warning Signs
View Full Analysis

What is Neurogene Retained Earnings?

Neurogene NGNE -7.49% 12 Retained Earnings is $-383.58 Mil as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Neurogene's retained earnings for the quarter that ended in Mar. 2026 was $-383.58 Mil.

Neurogene's quarterly retained earnings declined from Sep. 2025 ($-327.91 Mil) to Dec. 2025 ($-352.65 Mil) and declined from Dec. 2025 ($-352.65 Mil) to Mar. 2026 ($-383.58 Mil).

Neurogene's annual retained earnings declined from Dec. 2023 ($-187.15 Mil) to Dec. 2024 ($-262.30 Mil) and declined from Dec. 2024 ($-262.30 Mil) to Dec. 2025 ($-352.65 Mil).


Neurogene  (NAS:NGNE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Neurogene Retained Earnings Historical Data

* Premium members only.

The historical data trend for Neurogene's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Retained Earnings Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
-95.65 -150.84 -187.15 -262.30 -352.65

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -284.95 -306.96 -327.91 -352.65 -383.58
NGNE
12GF Score
Neurogene Inc NGNE
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-383.58 Mil mean?
Neurogene (NGNE) has a Retained Earnings of $-383.58 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Neurogene and its competitors.
Is Neurogene's Retained Earnings too high?
Neurogene's current Retained Earnings is $-383.58 Mil. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's Retained Earnings compare to STRO and OCGN?
Neurogene's Retained Earnings of $-383.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Neurogene and its competitors. Neurogene's current Retained Earnings is $-383.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current Retained Earnings of $-383.58 Mil. The current Retained Earnings is $-383.58 Mil. Neurogene's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Neurogene (NGNE), the current Retained Earnings is $-383.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.54
Price